[1]
|
Takeshita, J., Grewal, S., Langan, S.M., et al. (2017) Psoriasis and Comorbid Diseases: Epidemiology. Journal of the American Academy of Dermatology, 76, 377-390. https://doi.org/10.1016/j.jaad.2016.07.064
|
[2]
|
Bu, J., Ding, R., Zhou, L., Chen, X. and Shen, E. (2022) Epidemiology of Psoriasis and Comorbid Diseases: A Narrative Review. Frontiers in Immunology, 13, Article 880201. https://doi.org/10.3389/fimmu.2022.880201
|
[3]
|
Conrad, C. and Gilliet, M. (2018) Psoriasis: From Pathogenesis to Targeted Therapies. Clinical Reviews in Allergy & Immunology, 54, 102-113. https://doi.org/10.1007/s12016-018-8668-1
|
[4]
|
Johansen, C., Usher, P.A., Kjellerup, R.B., Lundsgaard, D., Iversen, L. and Kragballe, K. (2009) Characterization of the Interleukin-17 Isoforms and Receptors in Lesional Psoriatic Skin. British Journal of Dermatology, 160, 319-324. https://doi.org/10.1111/j.1365-2133.2008.08902.x
|
[5]
|
Blauvelt, A. and Chiricozzi, A. (2018) The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. Clinical Reviews in Allergy & Immunology, 55, 379-390. https://doi.org/10.1007/s12016-018-8702-3
|
[6]
|
Chang, S.H. and Dong, C. (2007) A Novel Heterodimeric Cytokine Consisting of IL-17 and IL-17F Regulates Inflammatory Responses. Cell Research, 17, 435-440. https://doi.org/10.1038/cr.2007.35
|
[7]
|
Bertelsen, T., Iversen, L. and Johansen, C. (2018) The Human IL-17A/F Heterodimer Regulates Psoriasis-Associated Genes through IκBζ. Experimental Dermatology, 27, 1048-1052. https://doi.org/10.1111/exd.13722
|
[8]
|
McGeachy, M.J., Cua, D.J. and Gaffen, S.L. (2019) The IL-17 Family of Cytokines in Health and Disease. Immunity, 50, 892-906. https://doi.org/10.1016/j.immuni.2019.03.021
|
[9]
|
Keijsers, R.R., Joosten, I., van Erp, P.E., Koenen, H.J. and van de Kerkhof, P.C. (2014) Cellular Sources of IL-17 in Psoriasis: A Paradigm Shift? Experimental Dermatology, 23, 799-803. https://doi.org/10.1111/exd.12487
|
[10]
|
Chiricozzi, A., De Simone, C., Fossati, B. and Peris, K. (2019) Emerging Treatment Options for the Treatment of Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis: Evaluating Bimekizumab and Its Therapeutic Potential. Psoriasis: Targets and Therapy, 9, 29-35. https://doi.org/10.2147/PTT.S179283
|
[11]
|
Mills, K.H.G. (2023) IL-17 and IL-17-Producing Cells in Protection versus Pathology. Nature Reviews Immunology, 23, 38-54. https://doi.org/10.1038/s41577-022-00746-9
|
[12]
|
Furue, M., Furue, K., Tsuji, G. and Nakahara, T. (2020) Interleukin-17A and Keratinocytes in Psoriasis. International Journal of Molecular Sciences, 21, Article 1275. https://doi.org/10.3390/ijms21041275
|
[13]
|
Lo, Y.H., Li, C.S., Chen, H.L., et al. (2021) Galectin-8 Is Upregulated in Keratinocytes by IL-17A and Promotes Proliferation by Regulating Mitosis in Psoriasis. Journal of Investigative Dermatology, 141, 503-511.E9. https://doi.org/10.1016/j.jid.2020.07.021
|
[14]
|
Ekman, A.K., Bivik Eding, C., Rundquist, I. and Enerbäck, C. (2019) IL-17 and IL-22 Promote Keratinocyte Stemness in the Germinative Compartment in Psoriasis. Journal of Investigative Dermatology, 139, 1564-1573.E8. https://doi.org/10.1016/j.jid.2019.01.014
|
[15]
|
Xu, X., Prens, E., Florencia, E., et al. (2021) Interleukin-17A Drives IL-19 and IL-24 Expression in Skin Stromal Cells Regulating Keratinocyte Proliferation. Frontiers in Immunology, 12, Article 719562. https://doi.org/10.3389/fimmu.2021.719562
|
[16]
|
Liu, Y., Zhang, C., Li, B., et al. (2021) A Novel Role of IL-17A in Contributing to the Impaired Suppressive Function of Tregs in Psoriasis. Journal of Dermatological Science, 101, 84-92. https://doi.org/10.1016/j.jdermsci.2020.09.002
|
[17]
|
Zhang, X., Angkasekwinai, P., Dong, C. and Tang, H. (2011) Structure and Function of Interleukin-17 Family Cytokines. Protein & Cell, 2, 26-40. https://doi.org/10.1007/s13238-011-1006-5
|
[18]
|
Monin, L. and Gaffen, S.L. (2018) Interleukin 17 Family Cytokines: Signaling Mechanisms, Biological Activities, and Therapeutic Implications. Cold Spring Harbor Perspectives in Biology, 10, a028522. https://doi.org/10.1101/cshperspect.a028522
|
[19]
|
Wright, J.F., Bennett, F., Li, B., et al. (2008) The Human IL-17F/IL-17A Heterodimeric Cytokine Signals through the IL-17RA/IL-17RC Receptor Complex. Journal of Immunology, 181, 2799-2805. https://doi.org/10.4049/jimmunol.181.4.2799
|
[20]
|
Maroof, A., Smallie, T., Archer, S., et al. (2017) Dual IL-17A and IL-17F Inhibition with Bimekizumab Provides Evidence for IL-17F Contribution to Immune-Mediated Inflammatory Skin Response. Journal of Investigative Dermatology, 137, S120. https://doi.org/10.1016/j.jid.2017.02.722
|
[21]
|
Glatt, S., Baeten, D., Baker, T., et al. (2018) Dual IL-17A and IL-17F Neutralisation by Bimekizumab in Psoriatic Arthritis: Evidence from Preclinical Experiments and a Randomised Placebo-Controlled Clinical Trial That IL-17F Contributes to Human Chronic Tissue Inflammation. Annals of the Rheumatic Diseases, 77, 523-532. https://doi.org/10.1136/annrheumdis-2017-212127
|
[22]
|
Maroof, A., Okoye, R., Smallie, T., et al. (2017) Bimekizumab Dual Inhibition of IL-17A and IL-17F Provides Evidence of IL-17F Contribution to Chronic Inflammation in Disease-Relevant Cells. Annals of the Rheumatic Diseases, 76, Article 213. https://doi.org/10.1136/annrheumdis-2017-eular.4966
|
[23]
|
Maroof, A., Baeten, D., Archer, S., Griffiths, M. and Shaw, S. (2017) IL-17F Contributes to Human Chronic Inflammation in Synovial Tissue: Preclinical Evidence with Dual IL-17A and IL-17F Inhibition with Bimekizumab in Psoriatic Arthritis. Annals of the Rheumatic Diseases, 76, A13. https://doi.org/10.1136/annrheumdis-2016-211050.13
|
[24]
|
Guilloteau, K., Paris, I., Pedretti, N., et al. (2010) Skin Inflammation Induced by the Synergistic Action of IL-17A, IL-22, Oncostatin M, IL-1α, and TNF-α Recapitulates Some Features of Psoriasis. Journal of Immunology, 184, 5263-5270. https://doi.org/10.4049/jimmunol.0902464
|
[25]
|
Christmann, C., Zenker, S., Martens, L., et al. (2021) Interleukin 17 Promotes Expression of Alarmins S100A8 and S100A9 during the Inflammatory Response of Keratinocytes. Frontiers in Immunology, 11, Article 599947. https://doi.org/10.3389/fimmu.2020.599947
|
[26]
|
Johnston, A., Fritz, Y., Dawes, S.M., et al. (2013) Keratinocyte Overexpression of IL-17C Promotes Psoriasiform Skin Inflammation. Journal of Immunology, 190, 2252-2262. https://doi.org/10.4049/jimmunol.1201505
|
[27]
|
Chiricozzi, A., Suárez-Fariñas, M., Fuentes-Duculan, J., et al. (2016) Increased Expression of Interleukin-17 Pathway Genes in Nonlesional Skin of Moderate-to-Severe Psoriasis Vulgaris. British Journal of Dermatology, 174, 136-145. https://doi.org/10.1111/bjd.14034
|
[28]
|
Van Baarsen, L.G., Lebre, M.C., van der Coelen, D., et al. (2014) Heterogeneous Expression Pattern of Interleukin 17A (IL-17A), IL-17F and Their Receptors in Synovium of Rheumatoid Arthritis, Psoriatic Arthritis and Osteoarthritis: Possible Explanation for Nonresponse to Anti-IL-17 Therapy? Arthritis Research & Therapy, 16, Article No. 426. https://doi.org/10.1186/s13075-014-0426-z
|
[29]
|
Reich, K., Papp, K.A., Blauvelt, A., et al. (2021) Bimekizumab versus Ustekinumab for the Treatment of Moderate to Severe Plaque Psoriasis (BE VIVID): Efficacy and Safety from a 52-Week, Multicentre, Double-Blind, Active Comparator and Placebo Controlled Phase 3 Trial. The Lancet, 397, 487-498. https://doi.org/10.1016/S0140-6736(21)00125-2
|
[30]
|
Warren, R.B., Blauvelt, A., Bagel, J., et al. (2021) Bimekizumab versus Adalimumab in Plaque Psoriasis. The New England Journal of Medicine, 385, 130-141. https://doi.org/10.1056/NEJMoa2102388
|
[31]
|
Reich, K., Warren, R.B., Lebwohl, M., et al. (2021) Bimekizumab versus Secukinumab in Plaque Psoriasis. The New England Journal of Medicine, 385, 142-152. https://doi.org/10.1056/NEJMoa2102383
|
[32]
|
Kokolakis, G., Warren, R.B., Strober, B., et al. (2023) Bimekizumab Efficacy and Safety in Patients with Moderate-to-Severe Plaque Psoriasis Who Switched from Adalimumab, Ustekinumab or Secukinumab: Results from Phase III/IIIb Trials. British Journal of Dermatology, 188, 330-340. https://doi.org/10.1093/bjd/ljac089
|